Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.

NCT03365791 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT03365791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03365791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 24, 2018
Completion date
September 17, 2020
Enrollment
76 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced well-differentiated neuroendocrine tumors, castration resistant prostate adenocarcinoma, diffuse large b cell lymphoma, esophageal adenocarcinoma, gastric adenocarcinoma, ovarian adenocarcinoma, small cell lung cancer, soft tissue sarcoma